A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors

Summary

This is a phase 1/2, open-label, multicenter study assessing the safety, tolerability, pharmacokinetics and efficacy of GW5282 in participants with locally advanced or metastatic solid tumors. This study comprised of a dose escalation phase to determine the MTD and the RP2D and a dose expansion phase to further explore the safety, PK and efficacy of GW5282.

Timeline

Start

2026-01-29

Primary completion

2028-12

Completion

2029-06

Drugs

Indications